Table 1.
Random sub-cohort (n=500) | Prevalence cohort (n=1905) | |
---|---|---|
Age, years, mean (±SD) | 42.8 (±16.8) | 48.8 (±17.5) |
| ||
Men, % | 255 (51%) | 921 (48%) |
| ||
Psoriasis characteristics at cohort entry, no (%) | ||
| ||
Prevalent patients | -- | 1245 (65%) |
| ||
Psoriatic arthritis* | 12 (2.4%) | 96 (5%) |
| ||
Plaque psoriasis | 380 (76%) | |
Other | 105 (21%) | |
Unknown | 15 (3%) | |
| ||
Nail involvement | 69 (14%) | |
| ||
Number of affected sites | 1.9 (±1.1) | |
| ||
Location | ||
Scalp | 214 (46%) | |
Trunk | 117 (25%) | |
Intergluteal perianal | 47 (10%) | |
| ||
Cardiovascular risk factors, no (%) | ||
| ||
Obesity | 117 (25%) | 476 (25%) |
| ||
Body Mass index, kg/m2, mean (±SD) | 27.2 (±6.0) | 28.3 (±6.4) |
≤20.0 | 28 (6%) | 77 (5%) |
20.1–24.9 | 161 (35%) | 408 (28%) |
25–29.9 | 160 (34%) | 471 (33%) |
30.0–34.9 | 66 (14%) | 269 (19%) |
≥35 | 51 (11%) | 207 (14%) |
| ||
Dyslipidemia | 213 (43%) | 630 (33%) |
| ||
Serum cholesterol, mg/dl, mean (±SD) | ||
Total cholesterol | 213.4 (±49) | 202 (±42) |
High-density lipoprotein cholesterol | 47.1 (±18.2) | 51 (±15) |
Low-density lipoprotein cholesterol | 129.5 (±35.9) | 118 (±36) |
Triglycerides | 159 (±201.2) | 166 (±109) |
| ||
Hypertension | 159 (32%) | 642 (34%) |
| ||
Blood pressure, mmHg, mean (±SD) | ||
Systolic | 128.7 (±20.0) | 128 (±20) |
Diastolic | 77.9 (±11.9) | 76 (±11) |
| ||
Diabetes mellitus | 28 (6%) | 257 (13%) |
| ||
Smoking status | ||
Current smoker | 179 (37%) | |
Former/ever smoker | 134 (27%) | |
Never smoked | 177 (36%) | |
| ||
Alcohol use | 83 (17%) | |
| ||
History of cardiovascular disease | 23 (5%) | 221 (12%) |
Heart failure | 8 (2%) | 39 (2%) |
Stroke | 3 (0.6%) | 136 (7%) |
MI or revascularization | 13 (3%) | 86 (5%) |
| ||
History of psoriasis treatment at baseline | ||
| ||
Phototherapy | -- | 21 (1%) |
Any systemic treatment | 82 (4%) |
Including patients who developed PSA during follow-up, there were a total of 30 PSA patients in the random sub-cohort and total 191 in the prevalence cohort over the entire follow-up period.